SELENOI

Across TCGA pan-cancer cohorts, SELENOI mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SELENOI data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SELENOI mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SELENOI expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

LUAD, HNSC, and UCEC are the cancer types where SELENOI mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.337	0.908	.002	17	view →
HNSC	DFS	Quartile	All	0.936	0.699	.015	14	view →
UCEC	OS	Tertile	II,III,IV	1.000	0.542	.010	8	view →
GBM	OS	Tertile	All	0.279	0.624	.021	4	view →
LSCC	OS	Median	II,III,IV	0.810	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SELENOI–LUAD (OS)

Open the LUAD breakdown →